- Home
- SRTS vs ARMP Comparison
SRTS vs ARMP Comparison
Compare SRTS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- ARMP
- Stock Information
- Founded
- SRTS 2010
- ARMP 2016
- Country
- SRTS United States
- ARMP United States
- Employees
- SRTS N/A
- ARMP N/A
- Industry
- SRTS Medical/Dental Instruments
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRTS Health Care
- ARMP Health Care
- Exchange
- SRTS Nasdaq
- ARMP Nasdaq
- Market Cap
- SRTS 88.7M
- ARMP 73.8M
- IPO Year
- SRTS 2016
- ARMP N/A
- Fundamental
- Price
- SRTS $4.77
- ARMP $1.58
- Analyst Decision
- SRTS Strong Buy
- ARMP Strong Buy
- Analyst Count
- SRTS 3
- ARMP 1
- Target Price
- SRTS $13.00
- ARMP $7.00
- AVG Volume (30 Days)
- SRTS 122.0K
- ARMP 14.4K
- Earning Date
- SRTS 05-08-2025
- ARMP 03-20-2025
- Dividend Yield
- SRTS N/A
- ARMP N/A
- EPS Growth
- SRTS 1266.06
- ARMP N/A
- EPS
- SRTS 0.41
- ARMP N/A
- Revenue
- SRTS $41,807,000.00
- ARMP $5,174,000.00
- Revenue This Year
- SRTS $9.09
- ARMP $8.43
- Revenue Next Year
- SRTS $22.30
- ARMP N/A
- P/E Ratio
- SRTS $11.71
- ARMP N/A
- Revenue Growth
- SRTS 71.31
- ARMP 14.24
- 52 Week Low
- SRTS $3.09
- ARMP $1.58
- 52 Week High
- SRTS $9.33
- ARMP $4.25
- Technical
- Relative Strength Index (RSI)
- SRTS 44.90
- ARMP 30.25
- Support Level
- SRTS $4.46
- ARMP $1.63
- Resistance Level
- SRTS $4.93
- ARMP $2.30
- Average True Range (ATR)
- SRTS 0.20
- ARMP 0.15
- MACD
- SRTS 0.09
- ARMP -0.04
- Stochastic Oscillator
- SRTS 69.35
- ARMP 0.00
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.